

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

pplication of:

Bolognesi et al.

Confirmation No.:

3907

Serial No.:

10/071,349

Art Unit:

1648

Filed:

February 6, 2002

Examiner: Jeffrey S. Parkin, Ph.D.

For:

METHODS FOR

Attorney

902445-999086

IDENTIFICATION OF CD8⁺

(formerly 7872-087-999)

SUPPRESSOR MOLECULES

Docket No.:

TERMINAL DISCLAIMER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Your Petitioner, Duke University, Assignee, is the owner of the above-identified application, by virtue of an assignment which was recorded in the U.S. Patent & Trademark Office on August 8, 2000 at Reel 011125, Frame 0217. This petition is made on behalf of and for the benefit of the assignee.

Petitioner hereby disclaims the terminal part of any patent granted on the above identified application which would extend beyond the expiration dates of U.S. Patent No. 6,586,174, U.S. Patent No. 5,861,490, and U.S. Patent No. 5,627,023; and hereby agrees that any patent so granted on the above identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to U.S. Patent No. 6,586,174, U.S. Patent No. 5,861,490 and U.S. Patent No. 5,627,023.

Petitioner further agrees that this agreement is to run with any patent granted on the above identified application and is to be binding upon the grantee, its successors, and assigns.

Petitioner does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration dates of the full statutory terms of U.S. Patent No. 6,586,174, U.S. Patent No. 5,861,490 or U.S. Patent No. 5,627,023, in the event should any of these patents later expire for failure to pay a maintenance fee, be held unenforceable, be found invalid, be statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), have all claims canceled by a reexamination certificate, or be otherwise terminated prior to the expiration of the respective full statutory terms, except for the separation of legal title stated above.

The undersigned is an attorney of record.

Date:

August 10, 2004

Respectfully submitted.

30,742

10071349

10071349

JONES DAY

(Reg. No.)

08/13/2004 MMEKONEN 00000045 503013 02 FC:1251

01 FC:1814

110.00 DA

110.00 DA

08/13/2004 MMEKONEN 00000046 503013

222 East 41st Street

New York, New York 10017 (212) 326-3939

NYJD: 1536512.1



Express Mail No. EV 452 773 103 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Bolognesi et al.

Confirmation No.:

3907

Serial No.:

10/071,349

Art Unit:

1648

Filed:

February 6, 2002

Examiner: Jeffrey S. Parkin, Ph.D.

For:

METHODS FOR

Attorney

902445-999086

IDENTIFICATION OF CD8⁺ SUPPRESSOR MOLECULES Docket No.:

(formerly 7872-087-999)

TERMINAL DISCLAIMER FEE TRANSMITTAL

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The fee for processing the attached Terminal Disclaimer is believed to be \$110.00. Please charge the required fee to Jones Day Deposit Account No. 50-3013. A copy of this sheet is attached for accounting purposes.

Date:

August 10, 2004

Respectfully submitted,

30,742

(Reg. No.)

Laura A. Coruzzi

JONES DAY

222 East 41st Street

New York, New York 10017

(212) 326-3939

nistas C. Luga Ng. Nr. 39, 20,